Market capitalization | $48.32m |
Enterprise Value | $75.65m |
P/E (TTM) P/E ratio | negative |
P/B ratio (TTM) P/B ratio | 0.96 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-29.62m |
Cash position | $17.68m |
EPS (TTM) EPS | $-3.11 |
P/E forward | negative |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
2 Analysts have issued a Aileron Therapeutics, Inc. forecast:
2 Analysts have issued a Aileron Therapeutics, Inc. forecast:
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.12 -0.12 |
9%
9%
|
|
EBITDA | -30 -30 |
133%
133%
|
EBIT (Operating Income) EBIT | -30 -30 |
132%
132%
|
Net Profit | -29 -29 |
126%
126%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Aileron Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead products candidate, ALRN-6924 which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky in June 2005 and is headquartered in Cambridge, MA.
Head office | United States |
CEO | Brian Windsor |
Employees | 15 |
Founded | 2001 |
Website | www.aileronrx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.